Table 4.

Late-onset and prolonged cytopenias (safety analysis set; n = 16)

Adverse event Preferred term	Any grade, n (%)	Grade ≥ 3, n (%)
Late-onset cytopeniasa
Thrombocytopeniab	12 (75.0)	10 (62.5)
Neutropeniac	11 (68.8)	11 (68.8)
Anemia	5 (31.3)	4 (25.0)
Febrile neutropenia	2 (12.5)	2 (12.5)
Prolonged cytopeniasd
Neutropeniac	3 (18.8)	3 (18.8)
Thrombocytopeniab	1 (6.3)	0 (0.0)
Anemia	1 (6.3)	0 (0.0)

Coded with MedDRA version 21.0

axi-cel axicabtagene ciloleucel, MedDRA Medical Dictionary for Regulatory Activities

^aLate-onset cytopenias were defined as any cytopenias present on or after 30 days of axi-cel infusion, including those that started after 30 days from axi-cel infusion and those that started earlier but were ongoing on or after 30 days of axi-cel infusion

^bThrombocytopenia includes thrombocytopenia and platelet count decreased

^cNeutropenia includes neutropenia and neutrophil count decreased

^dProlonged cytopenias were defined as any cytopenias with duration ≥ 30 days or any consecutive events of cytopenias with a combined duration ≥ 30 days